Echo is revolutionizing the quantified self.

We see a tremendous opportunty to deliver technology that will empower millions of people around the world to take better care of themselves and create a healthier world.

Corporate Profile

Echo Therapeutics is developing its non-invasive (transdermal & without needles), wireless, continuous glucose monitoring (CGM) system. A significant opportunity exists for the Company’s CGM to be used in the diabetes fitness, weight loss and personal lifestyle wearable-health space. Echo developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.

Effective July 12, 2016, Echo’s common stock will trade on the OTCQB® Venture Market, operated by OTC Markets Group Inc. under its current trading symbol “ECTE.” Beginning Tuesday, July 12, 2016, investors will be able to view real-time best bid and ask quotes for “ECTE” at and through most online broker websites.


View Corporate Presentation

Stock Prices